The Size of the Lyme Disease Diagnostic Market in the Asia Pacific is valued at USD xx Million in 2019 and is poised to reach USD xx Million by 2024, projected to grow at a CAGR of xx% during the forecast period 2019-2024.
Lyme disease is an infectious disease which is caused by bacteria Borrelia. It is a tick-borne disease caused by the bite of infected ticks. Fever, depression, fatigue and skin rashes are some of the symptoms of Lyme disease. It can be treated with antibiotics if it is diagnosed in early stages. But, if the disease is untreated then it affects heart, joint, and central nervous system and may cause death
Increasing incidences of Lyme diseaseis expected to be the major growth factor during the forecast period. However, inefficiency in Lyme disease testing is a major restraint.
Asia Pacific Lyme Disease Diagnostic Market has been segmented and sub-segmented into the following categories
On the basis of region, the Asia Pacific has significant growth owing to the growing population.
Top Companies dominating the Asia Pacific Lyme Disease Diagnostics Market Profiled in the Report are Boulder Diagnostics, Immunetics Inc, GlaxoSmithKline Pharmaceuticals Ltd, Bio-Rad Laboratories, Alere Inc (ALR), Roche Diagnostics International Ltd, Graphene Frontiers, Covance Inc, Affymetrix Inc, Siemens AG, Baxter International Inc, Fresenius Medical Care AG & Co.,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Tests
5.1.1 Introduction
5.1.2 Serological tests
5.1.2.1 ELISA (Enzyme-linked Immunosorbent Assay)
5.1.2.2 ELFA (Enzyme-linked Fluorescent Immunoassay)
5.1.2.3 Western Blot
5.1.3 Lymphocytic transformation test
5.1.4 Immunofluorescence staining
5.1.5 PCR Analysis
5.1.6 Urine antigen tests
5.1.7 Darkfield microscopy
5.1.8 Y-o-Y Growth Analysis, By Diagnostic Tests
5.1.9 Market Attractiveness Analysis, By Diagnostic Tests
5.1.10 Market Share Analysis, By Diagnostic Tests
5.2 Diagnostic Technologies
5.2.1 Introduction
5.2.2 Molecular diagnostics
5.2.3 Brain MRI
5.2.4 Spinal tap
5.2.5 Echocardiogram
5.2.6 Electrocardiogram
5.2.7 Monoclonal antibodies
5.2.8 Flow cytometry
5.2.9 Gel micro droplets
5.2.10 Y-o-Y Growth Analysis, By Diagnostic Technologies
5.2.11 Market Attractiveness Analysis, By Diagnostic Technologies
5.2.12 Market Share Analysis, By Diagnostic Technologies
5.3 End Users
5.3.1 Introduction
5.3.2 Hospitals / Clinics
5.3.3 Pharmaceutical Industries
5.3.4 Pathology labs
5.3.5 Research Institutes
5.3.6 Y-o-Y Growth Analysis, By End Users
5.3.7 Market Attractiveness Analysis, By End Users
5.3.8 Market Share Analysis, By End Users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Diagnostic Tests
6.1.3.3 By Diagnostic Technologies
6.1.3.4 By End Users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Diagnostic Tests
6.1.4.3 By Diagnostic Technologies
6.1.4.4 By End Users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Diagnostic Tests
6.1.5.3 By Diagnostic Technologies
6.1.5.4 By End Users
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
6.7 Rest of APAC
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Siemens AG
8.3 GlaxoSmithKline Pharmaceuticals Ltd.
8.4 Fresenius Medical Care AG & Co.
8.5 Baxter International Inc.
8.6 Affymetrix Inc.
8.7 Immunetics Inc.
8.8 Boulder Diagnostics
8.9 Roche Diagnostics International Ltd.
8.10 Canon U.S. Life Sciences
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
